42Stockpicking
NASDAQ·Healthcare·USD

Henter pris…

Værdiansættelse (TTM)

P/Ei
1,1
2nd %ile · 158p
EV/EBITDAi
0,0
1st %ile · 83p
P/Bi
P/Si
EV/Salesi
Div yieldi
35,9 %
98th %ile · 60p

Kursudvikling

Kun 1100 handelsdage i databasen.

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 10.6.2026basic
Prishistorik
4,2 år
Pris-dage
1057
Årsregnskaber
7
Peers
0/0
Valuation
3/6
Fundamentals
8/8
Datovindue
2022-03-22 til 2026-06-08

Blokkere

  • Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

  • Mangler ca. 5,8 års prishistorik før ideal/full.
  • Backfill mod 5 års priser for strong-readiness.
  • Kør compute-multiples for manglende valuation metrics.

Seneste assessment

EMBC vurderet 2026-06-10

Score
42.0%
Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

40%

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

34%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

5%

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

76%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

46%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

46%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

74%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: Own P/E 1.1 vs peer median 15.7; cheaper than peers if business quality is comparable.

Insider activity

Net 90d (aktier)
115.000
Net 90d (værdi)
557.945 USD
Købere 90d
4
Cluster buy
DatoPersonRolleTypeAntalVærdiKilde
12.8.2026HOMBACH ROBERT J.▲ KØB45.000223.848 USDsec
12.8.2026Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLO▲ KØB20.00099.800 USDsec
12.8.2026Elguicze JacobSVP and CFO▲ KØB20.00093.360 USDsec
12.8.2026Kurdikar DevdattPresident and CEO▲ KØB30.000140.937 USDsec
9.8.2026Casner JeanChief Human Resources Officer· ANDET-1.480-6.542 USDsec
1.6.2026Roth Anthony M.VP, Chief Accounting Officer· ANDET30.000sec

Earnings

QuarterDateEPS actualEPS estEPS surpriseRevenue surprise
2026Q130.4.20260,270,42-35.3%-35.3%Miss
2025Q430.1.20260,710,67+6.0%+6.0%Beat
2025Q330.10.20250,500,46+9.9%+9.9%Beat
2025Q230.7.20251,120,78+44.5%+44.5%Beat